These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24910212)

  • 21. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
    Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
    Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
    Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
    J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
    [No Abstract]   [Full Text] [Related]  

  • 25. Estimation of Health-Related Utilities for
    Soare IA; Leeuwenkamp O; Longworth L
    Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
    Huang D; Zeng D; Tang Y; Jiang L; Yang Q
    Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
    Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
    PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
    Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J
    Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression Methods.
    Crott R
    Pharmacoecon Open; 2018 Jun; 2(2):165-177. PubMed ID: 29623623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
    Wu EQ; Mulani P; Farrell MH; Sleep D
    Value Health; 2007; 10(5):408-14. PubMed ID: 17888106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.
    Young TA; Mukuria C; Rowen D; Brazier JE; Longworth L
    Med Decis Making; 2015 Oct; 35(7):912-26. PubMed ID: 25997920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
    Kay S; Ferreira A
    Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
    Yousefi M; Nahvijou A; Sari AA; Ameri H
    Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas.
    Xu RH; Wong ELY; Jin J; Dou Y; Dong D
    Eur J Health Econ; 2020 Dec; 21(9):1363-1373. PubMed ID: 32960388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
    Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
    Lloyd AJ; Kerr C; Penton J; Knerer G
    Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
    Skaltsa K; Longworth L; Ivanescu C; Phung D; Holmstrom S
    Value Health; 2014 Mar; 17(2):238-44. PubMed ID: 24636382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
    Rowen D; Young T; Brazier J; Gaugris S
    Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer.
    Noel CW; Keshavarzi S; Forner D; Stephens RF; Watson E; Monteiro E; Hosni A; Hansen A; Goldstein DP; de Almeida JR
    Otolaryngol Head Neck Surg; 2022 May; 166(5):877-885. PubMed ID: 34311628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.